Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Cancer therapies and diagnostics group Avacta entered into a global distribution agreement with ABCAM to sell the company'sSARS-CoV-2 research Affimer reagents.
Under the worldwide, non-exclusive distribution agreement, ABCAM would enable the global research community to access Avacta's SARS-CoV-2 spike protein Affimer research reagents through its on-line catalogue.
At 9:26am: (LON:AVCT) Avacta Group PLC share price was 0p at 111.5p